The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)

被引：0
|
作者：
Abuhadra, N. [1 ]
Sun, R. [2 ]
Litton, J. K. [1 ]
Rauch, G. [3 ]
Thompson, A. M. [4 ]
Lim, B. [1 ]
Adrada, B. [3 ]
Mittendorf, E. [5 ]
Damodaran, S. [6 ]
Pitpitan, R. [3 ]
Arun, B. [7 ]
White, J. [1 ]
Ravenberg, E. [1 ]
Santiago, L. [3 ]
Sahin, A. [8 ]
Murthy, R. [6 ]
Ueno, N. T. [1 ]
Ibrahim, N. [1 ]
Moulder, S. [1 ]
Huo, L. [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Div Diagnost Imaging, Dept Diagnost Radiol, Houston, TX 77030 USA
[4] Baylor Coll Med, Breast Surg Oncol, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Surg, 75 Francis St, Boston, MA 02115 USA
[6] MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX USA
[7] MD Anderson Canc Ctr, Breast Med Oncol & Clin Canc Genet, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
98O
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 35 条
  • [21] Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
    Abdullaeva, S.
    Semiglazova, T. Y.
    Artemyeva, A.
    Kudaibergenova, A.
    Semiglazov, V.
    Krivorotko, P.
    Semiglazov, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S288 - S289
  • [22] Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.
    Barroso-Sousa, Romualdo
    de Sousa, Isadora Martins
    Marin Comini, Ana Carolina
    Tavares, Monique Celeste
    Pinheiro, Fernanda Madasi
    Bines, Jose
    Ferreira, Rafael Dal Ponte
    Rosa, Daniela Dornelles
    Santos, Candice Lima
    Souza, Zenaide Silva
    Suzuki, Daniele Assad
    Pereira de Araujo, Julio Antonio
    Gagliato, Debora De Melo
    Dos Anjos, Carlos Henrique
    Zucchetti, Bruna M.
    Rubin de Celis Ferrari, Anezka Carvalho
    De Brito, Mayana Lopes
    Monteiro, Maria Marcela F.
    Testa, Laura
    Bonadio, Renata Colombo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Pathological complete response after carboplatin-based neoadjuvant chemotherapy in triple negative breast cancer: The importance of stromal tumor infiltrating lymphocytes as a predictive biomarker
    Walsh, Elaine M.
    O'Loughlin, Mark
    Shalaby, Aliaa
    Webber, Mark
    Kerin, Michael J.
    Glynn, Sharon A.
    Callagy, Grace
    Keane, Maccon M.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Effect of taxanes following anthracyclines on pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC) receiving primary systemic therapy (PST)
    Gildetti, S.
    Natoli, C.
    Zilli, M.
    Grassadonia, A.
    Tinari, N.
    Scognamiglio, M.
    Giampietro, J.
    Angelucci, D.
    Cianchetti, E.
    Iacobelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
    Abuhadra, Nour
    Sun, Ryan
    Litton, Jennifer K.
    Rauch, Gaiane M.
    Yam, Clinton
    Chang, Jeffrey T.
    Seth, Sahil
    Bassett, Roland, Jr.
    Lim, Bora
    Thompson, Alastair M.
    Mittendorf, Elizabeth
    Adrada, Beatriz E.
    Damodaran, Senthil
    White, Jason
    Ravenberg, Elizabeth
    Candelaria, Rosalind
    Arun, Banu
    Ueno, Naoto T.
    Santiago, Lumarie
    Saleem, Sadia
    Abouharb, Sausan
    Murthy, Rashmi K.
    Ibrahim, Nuhad
    Sahin, Aysegul A.
    Valero, Vicente
    Symmans, William Fraser
    Tripathy, Debu
    Moulder, Stacy
    Huo, Lei
    CANCERS, 2022, 14 (05)
  • [26] A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST)
    Moulder, S.
    Adrada, B.
    Lim, B.
    Ueno, N.
    Candelaria, R.
    Rauch, G.
    Litton, J.
    Thompson, A.
    Huo, L.
    Hess, K.
    BREAST, 2019, 44 : S101 - S102
  • [27] Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).
    Lee, Hee Jin
    Cho, Soo Yoon
    Cho, Eun Yoon
    Lim, Yoojoo
    Cho, Soo Ick
    Jung, Wonkyung
    Song, Sanghoon
    Kang, Mingu
    Ryu, Jeongun
    Ma, Minuk
    Park, Seonwook
    Paeng, Kyunghyun
    Ock, Chan-Young
    Song, Sang Yong
    Gong, Gyungyub
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials
    Furlanetto, J.
    Denkert, C.
    Untch, M.
    Sinn, B.
    Lederer, B.
    Schneeweiss, A.
    Mueller, V.
    van Mackelenbergh, M.
    Stickeler, E.
    Fasching, P. A.
    Schem, C.
    Karn, T.
    Marme, F.
    Nekljudova, V.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S27 - S28
  • [29] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2019, 30
1234